Mast Therapeutics, Inc. (MSTX)

[LaJollaCA]

From MSTX 7th Annual OneMedForum Emerging Company Finance Conference

http://www.masttherapeutics.com/wp-content/uploads/2012/09/MastThera_CorpPres_01.14.2014.pdf

Look at page 7 and 26:

Open First EPIC Site Outside the U.S. Q1 ’14
Report Biomarker Data from Heart Failure Study Q1 ’14
Initiate Phase 2 Study in Acute Limb Ischemia Q1 ’14
Outcome from U.S. Adopted Names Council Review of Unique Designation for Purified Poloxamer 188 Q1 ’14

Provide Details of Heart Failure Study at Major Medical Conference Q2 ’14
Request Orphan Designation for ALI in EU (Received in U.S.) Q2 ‘14
Announce Clinical Development Strategy in Heart Failure Q2 ’14
Initiate Nonclinical POC Study in Resuscitation Q2 '14